Qing Danielle Y, Conegliano David, Shashaty Michael G S, Seo Jeongyun, Reilly John P, Worthen G Scott, Huh Dongeun, Meyer Nuala J, Mangalmurti Nilam S
1 Pulmonary, Allergy and Critical Care Division, Perelman School of Medicine, and.
Am J Respir Crit Care Med. 2014 Dec 1;190(11):1243-54. doi: 10.1164/rccm.201406-1095OC.
Red blood cell (RBC) transfusions are associated with increased risk of acute respiratory distress syndrome (ARDS) in the critically ill, yet the mechanisms for enhanced susceptibility to ARDS conferred by RBC transfusions remain unknown.
To determine the mechanisms of lung endothelial cell (EC) High Mobility Group Box 1 (HMGB1) release following exposure to RBCs and to determine whether RBC transfusion increases susceptibility to lung inflammation in vivo through release of the danger signal HMGB1.
In vitro studies examining human lung EC viability and HMGB1 release following exposure to allogenic RBCs were conducted under static conditions and using a microengineered model of RBC perfusion. The plasma from transfused and nontransfused patients with severe sepsis was examined for markers of cellular injury. A murine model of RBC transfusion followed by LPS administration was used to determine the effects of RBC transfusion and HMGB1 release on LPS-induced lung inflammation.
After incubation with RBCs, lung ECs underwent regulated necrotic cell death (necroptosis) and released the essential mediator of necroptosis, receptor-interacting serine/threonine-protein kinase 3 (RIP3), and HMGB1. RIP3 was detectable in the plasma of patients with severe sepsis, and was increased with blood transfusion and among nonsurvivors of sepsis. RBC transfusion sensitized mice to LPS-induced lung inflammation through release of the danger signal HMGB1.
RBC transfusion enhances susceptibility to lung inflammation through release of HMGB1 and induces necroptosis of lung EC. Necroptosis and subsequent danger signal release is a novel mechanism of injury following transfusion that may account for the increased risk of ARDS in critically ill transfused patients.
在危重症患者中,红细胞(RBC)输血与急性呼吸窘迫综合征(ARDS)风险增加有关,但RBC输血导致ARDS易感性增强的机制尚不清楚。
确定肺内皮细胞(EC)在暴露于RBC后高迁移率族蛋白B1(HMGB1)释放的机制,并确定RBC输血是否通过释放危险信号HMGB1增加体内对肺部炎症的易感性。
在静态条件下并使用RBC灌注的微工程模型,进行体外研究,检测人肺EC在暴露于同种异体RBC后的活力和HMGB1释放。检测严重脓毒症输血和未输血患者血浆中的细胞损伤标志物。使用RBC输血后给予脂多糖(LPS)的小鼠模型,确定RBC输血和HMGB1释放对LPS诱导的肺部炎症的影响。
与RBC孵育后,肺EC发生程序性坏死性细胞死亡(坏死性凋亡),并释放坏死性凋亡的关键介质受体相互作用丝氨酸/苏氨酸蛋白激酶3(RIP3)和HMGB1。在严重脓毒症患者的血浆中可检测到RIP3,且在输血患者和脓毒症非幸存者中升高。RBC输血通过释放危险信号HMGB1使小鼠对LPS诱导的肺部炎症敏感。
RBC输血通过释放HMGB1增强对肺部炎症的易感性,并诱导肺EC发生坏死性凋亡。坏死性凋亡及随后的危险信号释放是输血后损伤的一种新机制,这可能解释了危重症输血患者ARDS风险增加的原因。